Urokinase

Summary

Urokinase (CHEMBL1201420) is an approved enzyme (ATC B01AD04); indicated across 7 conditions including thrombotic disease and empyema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: B01AD04
• Indications: 7 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201420
Name	Urokinase
Type	Enzyme
Max phase	4
ATC	B01AD04

Also known as: Abbokinase, Kinase (enzyme-activating), uro-, Kinlytic, Ukidan, Urinary plasminogen activator, Urokinase, Uroquinasa, UROKINASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
empyema	3	MONDO:0005242	EFO:0003097
stroke disorder	3	MONDO:0005098	EFO:0000712
pulmonary embolism	2	MONDO:0005279	EFO:0003827
ST-elevation myocardial infarction	2	MONDO:0041656	EFO:0008585
pleural empyema	2	MONDO:0018667	EFO:0009680

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE3	6
Not specified	6
PHASE4	5
PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06284642	PHASE4	RECRUITING	Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
NCT00799968	PHASE4	COMPLETED	12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China
NCT00968929	PHASE4	COMPLETED	Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
NCT01568931	PHASE4	UNKNOWN	Local Thrombolytics Before Thrombectomy in STEMI
NCT06802679	PHASE4	COMPLETED	Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: A Randomized Controlled Trial
NCT00502632	PHASE2/PHASE3	UNKNOWN	Dornase Alfa and Urokinase for Kids With Pleural Empyema
NCT00798278	PHASE3	COMPLETED	Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood
NCT00823225	PHASE3	TERMINATED	Urokinase Therapy in Patients With Diabetic Foot Syndrome
NCT01134237	PHASE3	UNKNOWN	Intrapleural Urokinase for Retained Hemothorax
NCT01638585	PHASE3	TERMINATED	Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia
NCT02036255	PHASE3	COMPLETED	Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase
NCT04420351	PHASE3	COMPLETED	Thrombolysis of Urokinase for Minor Stroke
NCT00537498	PHASE2	COMPLETED	Urokinase Therapy in Diabetic Foot Syndrome
NCT04516993	PHASE2	COMPLETED	CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II
NCT06194968	Not specified	RECRUITING	Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
NCT07047326	Not specified	RECRUITING	Urokinase for Thrombolysis in Acute Ischemic Stroke
NCT02414802	Not specified	UNKNOWN	Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis
NCT02854592	Not specified	COMPLETED	Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
NCT03997292	Not specified	WITHDRAWN	Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China
NCT04792944	Not specified	COMPLETED	Brain Aneurysms: Utility of Cisternal Urokinase Irrigation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).